DoorDash stock dips on year-end slide as markets shut for New Year’s Day — what’s next for DASH

DoorDash stock dips on year-end slide as markets shut for New Year’s Day — what’s next for DASH

NEW YORK, January 1, 2026, 17:00 ET — Market closed

  • DoorDash (DASH) last closed down 0.7% at $226.48 in the final U.S. session of 2025.
  • U.S. stock markets are closed Thursday for New Year’s Day, with trading set to resume Friday. 1

DoorDash, Inc. shares ended the last trading day of 2025 lower, mirroring a broad pullback that capped the year in thin holiday-week trading.

The move matters because the first trading sessions of 2026 will test whether investors keep trimming higher-growth consumer internet names or rotate back into them as liquidity returns.

For DoorDash, the near-term focus remains demand momentum and cost discipline, two drivers that can swing expectations quickly when the market’s appetite for risk shifts.

DASH finished at $226.48 on Wednesday, down 0.7% from the prior close, with about 2.45 million shares traded, according to market data.

Wall Street’s major indexes also ended the year lower on Wednesday, with the S&P 500 down 0.74%, the Nasdaq off 0.76% and the Dow down 0.63%, Reuters reported. 2

“I do not expect that the last few days will have so much bearing on the performance of the next year,” said Giuseppe Sette, co-founder and president of Reflexivity, pointing to profit-taking when liquidity was low. 2

The holiday calendar amplified the moves. The NYSE lists New Year’s Day, Thursday, January 1, as a U.S. market holiday. 1

Separately, DoorDash is heading into 2026 with ongoing scrutiny on how delivery platforms handle pay and tips. New York’s attorney general said the deadline for eligible Dashers to file claims tied to a $16.75 million settlement was December 31, 2025. 3

When markets reopen, traders will be watching whether DASH reclaims the $230 area quickly or stays pinned below it as investors reassess growth exposure after the year-end pullback.

Macro data is also in view. The U.S. Employment Situation report for December 2025 is scheduled for Friday, January 9, at 8:30 a.m. ET, a release that can move rate expectations and consumer-spending sentiment. 4

On the policy front, the Federal Reserve’s 2026 calendar shows the next FOMC meeting scheduled for January 27–28. 5

DoorDash has not announced a date for its next earnings release; Nasdaq’s earnings page shows an estimated report date of February 10, 2026, based on an algorithm using historical reporting patterns. 6

Technically, DASH is coming into 2026 after trading Wednesday between $226.08 and $228.50, leaving that band as an early reference point for support and resistance as volume returns.

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
Apple stock forecast for 2026: Can AAPL reach $350 as AI questions linger?
Previous Story

Apple stock forecast for 2026: Can AAPL reach $350 as AI questions linger?

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug
Next Story

Axsome Therapeutics (AXSM) stock jumps after FDA sets April 30 decision for Alzheimer’s agitation drug

Go toTop